Suppr超能文献

糖尿病高血压研究IV。维持严格血压控制的治疗要求。

Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.

出版信息

Diabetologia. 1996 Dec;39(12):1554-61. doi: 10.1007/s001250050614.

Abstract

We report the efficacy of therapy over 5 years follow-up in 758 non-insulin-dependent diabetic patients in a prospective, randomised controlled study of therapy of mild hypertension. Patients were recruited who on antihypertensive therapy had systolic blood pressure over 150 mmHg or diastolic over 85 mmHg, or if not on therapy had systolic blood pressure over 160 mmHg or diastolic over 90 mmHg. Their mean blood pressure at entry to the study was 160/94 mmHg at a mean age of 57 years. They were allocated to tight control (aiming for systolic < 150/diastolic < 85 mmHg) or to less tight control (aiming for systolic < 180/diastolic < 105 mmHg). The tight control group were allocated to primary therapy either with a beta blocker (atenolol) or with an antiotensin converting enzyme inhibitor (captopril), with addition of other agents as required. Over 5 years, the mean blood pressure in the tight control group was significantly lower (143/82 vs 154/88 mmHg, p < 0.001). No difference was seen between those allocated to atenolol or captopril. The proportion of patients requiring three or more antihypertensive therapies to maintain tight control in those allocated to atenolol or captopril increased from 16 and 15%, respectively at 2 years to 25 and 26%, respectively at 5 years, whereas in the less tight control group at 2 and 5 years only 5 and 7%, respectively required three or more therapies. There was no difference in the incidence of side effects or hypoglycaemic episodes between those allocated to atenolol or captopril, but those allocated to atenolol increased their body weight by a mean of 2.3 kg compared with 0.5 kg in those allocated to captopril (p < 0.01). Allocation to atenolol was also associated with small increases in triglyceride, and decreases in LDL and HDL cholesterol, which are of uncertain clinical relevance. The study is continuing to determine whether the improved blood pressure control, which was obtained, will be beneficial in maintaining the health of patients by decreasing the incidence of major clinical complications, principally myocardial infarction and strokes, and microvascular complications, such as severe retinopathy requiring photocoagulation and deterioration of renal function.

摘要

在一项针对轻度高血压治疗的前瞻性随机对照研究中,我们报告了758例非胰岛素依赖型糖尿病患者5年随访期内的治疗效果。招募的患者若正在接受抗高血压治疗,收缩压超过150 mmHg或舒张压超过85 mmHg;若未接受治疗,收缩压超过160 mmHg或舒张压超过90 mmHg。他们进入研究时的平均血压为160/94 mmHg,平均年龄为57岁。将他们分为严格控制组(目标为收缩压<150/舒张压<85 mmHg)和较宽松控制组(目标为收缩压<180/舒张压<105 mmHg)。严格控制组被分配接受β受体阻滞剂(阿替洛尔)或血管紧张素转换酶抑制剂(卡托普利)作为初始治疗,并根据需要添加其他药物。5年间,严格控制组的平均血压显著更低(143/82 vs 154/88 mmHg,p<0.001)。分配接受阿替洛尔或卡托普利治疗的患者之间未见差异。分配接受阿替洛尔或卡托普利治疗的患者中,为维持严格控制而需要三种或更多抗高血压治疗的比例分别从2年时的16%和15%增至5年时的25%和26%,而在较宽松控制组,2年和5年时分别仅有5%和7%的患者需要三种或更多治疗。分配接受阿替洛尔或卡托普利治疗的患者在副作用或低血糖发作发生率上无差异,但分配接受阿替洛尔治疗的患者体重平均增加2.3 kg,而分配接受卡托普利治疗的患者体重平均增加0.5 kg(p<0.01)。分配接受阿替洛尔治疗还与甘油三酯小幅升高以及低密度脂蛋白和高密度脂蛋白胆固醇降低有关,其临床相关性尚不确定。该研究仍在继续,以确定所实现的血压改善控制是否会通过降低主要临床并发症(主要是心肌梗死和中风)以及微血管并发症(如需要光凝治疗的严重视网膜病变和肾功能恶化)的发生率,对维持患者健康有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验